With time at a premium for health care workers and support staff, we are sharing this list of key resources for our cancer clinical trials community. We welcome your comments and suggestions at pbzzhavpngvbaf/ng/fjbt/qbg/bet

This list is updated weekly

SWOG Communications

*LATEST Memorandum January 25, 2021 Guidance on SWOG Trials and COVID-19 Vaccines

SWOG Active Protocol Specimen Guidance April 22, 2021

SWOG Lab and Bank Status June 1, 2021

Memorandum July 30, 2020 Canadian Cancer Trials Group Collection of COVID-19 Test Results

Form June 26, 2020 PDF Version of SWOG COVID-19 Diagnosis and Protocol Deviations Form

Memorandum June 26, 2020 SWOG COVID-19 Diagnosis and Protocol Deviations Form

Memorandum June 16, 2020 NRG Oncology Reopens Serum Bank

Memorandum June 15, 2020 Interim COVID-19 Guidance for SWOG Trials

SWOG COVID Deviation Log in PDF form April 27, 2020

Site Memorandum April 20, 2020 SWOG COVID-19 for Eligibility Visits and H&P Assessments

Site Memorandum April 20, 2020 SWOG COVID-19 Deviation Guidance

Site Memorandum April 15, 2020 Updated Guidance for SWOG Trials

Site Memorandum March 24, 2020 Guidance for SWOG Trials During COVID-19 Pandemic

For Cancer Physicians, Investigators, and Site Staff

*LATEST NCCN Issues Guidelines on COVID-19 Vaccination for Cancer Patients (version 4) August 30, 2021

NCI Guidance on Shipment of Oral IND Agents to Patients on Clinical Trials August 28, 2020

CTEP Shipment of Oral IND Agents Site Memorandum April 30, 2021

CIRB Updated FAQ April 22, 2020

American College of Surgeons March 21, 2020 COVID19 Guidance and Resources

American Medical Association Resources to Physicians Regarding Coronavirus March 20, 2020

American Society of Clinical Oncology Coronavirus Resources March 20, 2020
One Site for Clinical Care, Policy Updates, Meeting and More

American Society for Radiation Oncology March 16, 2020 Guidance and Resources

Association of Community Cancer Centers March 27, 2020 Coronavirus Response

COVID-19 Treatment Hub April 15, 2020 Info compilation on COVID-19 studies testing vaccines and drugs

National Cancer Institute Joint Meeting of Scientific Board of Advisors & National Cancer Advisory Board
April 9, 2020
Dr. Ned Sharpless slide presentation
Dr. Doug Lowy slide presentation
Dr. James Doroshow slide presentation

National Cancer Institute COVID-19 Guidance for Extramural and Intramural Research NCI's March 13 and March 23 interim guidance memos, as well as other statements and updates, can be found on that site, and also here

National Institutes of Health Guidance March 16, 2020 NIH-Funded Clinical Trials and Human Subjects Studies

National Comprehensive Cancer Network March 24, 2020 COVID-19 Resources

Oncology Nursing Society March 20, 2020 Interim Guidelines During COVID-19 Pandemic

U.S. Food & Drug Administration FINAL Guidance March 2020 On Conducting Clinical Trials During Pandemic

U.S. FDA Oncology Center of Excellence March 23, 2020 COVID-19 Message

For Cancer Patients

ASCO Cancer.Net What People With Cancer Need to Know by Dr. Merry Jennifer Markham

ASCO Cancer.Net Common Questions About Coronavirus and Cancer: Answers for Patients and Survivors

Cancer Support Community What Cancer Patients, Survivors, and Caregivers Need

Centers for Disease Control and Prevention How to Protect Yourself

National Cancer Institute Coronavirus: What People With Cancer Should Know

National Cancer Institute Emergency Resources for the Cancer Community

National Institutes of Health Health Information on Coronavirus

Substance Abuse and Mental Health Services Administration Taking Care of Your Behavioral Health: Social Distancing, Quarantine, and Isolation in an Infectious Disease Outbreak

U.S. Department of Veterans Affairs VA Response to Coronavirus for Patients Receiving VA Care

Cancer Research and COVID-19

ASCO Survey on COVID-19 in Oncology Registry All U.S. Practices Can Enroll for Real-Time and Long-Term Data on Impact of COVID-19 on Cancer Care

COVID-19 and Cancer Consortium Data Collection on Cancer Patients Infected with COVID-19

Journal of the American Medical Association Latest Results on Coronavirus (COVID-19)

New England Journal of Medicine COVID-19: NEJM Journal Watch Coverage

PubMed Free Access to Articles From Highly Accessed Journals, Including Research on COVID-19

Science Magazine Research, Evidence, and Data on COVID-19 Free access to literature

Oncology News

*LATEST STAT News, November 29, 2021 With Winter Looming, Cancer Patients and Doctors Seek More Covid Protection

HealthDay, November 19, 2021 COVID Booster Shot Helps Cancer Patients

Scientific American, November 16, 2021 The COVID Cancer Effect

US News & World Report, November 12, 2021 More Evidence That COVID Vaccines Are Safe for Cancer Patients

AP News, November 2, 2021 No, COVID-19 Vaccines Don’t Cause HIV, AIDS or Cancer

STAT News, October 29, 2021 Watch: When Disease Impairs Immunity, Vaccines Are Hampered, Too

CNN, October 18, 2021 Why Colin Powell's Cancer Likely Reduced His Protection from the Covid-19 Vaccine

Washington Post, October 11, 2021 Covid and Cancer: A Dangerous Combination, Especially for People of Color

CNN, October 8, 2021 Don't Panic if You Get Swollen Lymph Nodes after a Vaccine Booster. But Be Aware of You're Due for a Mammogram, Doctors Say

USA Today, September 27, 2021 Fact check: False claim that cancer has spiked as a result of COVID-19 vaccines

UPI, September 16, 2021 Study: Blood Cancer Patients May Benefit from COVID-19 Vaccine Booster

US News & World Report, September 8, 2021 In Cancer Patients, COVID Vaccine Immunity at 6 Months Is Similar to General Population

Medscape, August 30, 2021 NCCN Recommends Third COVID-19 Dose for Patients With Cancer

HealthDay, August 20, 2021 COVID-19 Immune Response Appears Strong in Cancer Patients

New York Times, August 13, 2021 C.D.C. Panel Recommends Third Dose of Covid Vaccine for Immunocompromised

Other Recent Stories

SWOG Front Line Banner
Dec 3, 2021
Effectively joining SWOG’s work: A how-to for young investigators
RxPONDER Trial Results: Kevin Kalinsky, MD
Dec 1, 2021
RxPONDER finds postmenopausal women with HR+, HER2- breast cancer with 1-3 involved nodes and an RS of 25 or less can safely skip chemo